Skip to content
Search
Close
Menu

Kevin Pan, Ph.D.

  • About Us
  • Pipeline
  • Technology
  • News & Media
  • Partnership
  • Investors
  • Join Us
  • Contact Us
  • Term of Use
  • Privacy
Weixin
Linkedin-in Twitter Envelope

@2014-2023 Asieris Pharmaceuticals. All Rights Reserved.

Home
  • English
    • English
    • 中文
  • English
    • English
    • 中文
  •  English
    •       English
    •       中文
  • About Us
    • Our Mission
    • Our Values
    • Timeline
    • Management
    • ESG System
  • Pipeline
    • Urological Diseases
    • Gynecological Diseases
    • Other Diseases
    • Bladder Cancer
    • Precancerous Cervical Dysplasia
  • Technology
    • TIMN
    • PADD
    • FASTac
  • News
    • News
    • Awards
    • Media
    • PR Contact
  • Partnership
    • Collaboration
    • Contact us
  • Investors
  • Join Us
    • Openings
  • Contact
  • About Us
    • Our Mission
    • Our Values
    • Timeline
    • Management
    • ESG System
  • Pipeline
    • Urological Diseases
    • Gynecological Diseases
    • Other Diseases
    • Bladder Cancer
    • Precancerous Cervical Dysplasia
  • Technology
    • TIMN
    • PADD
    • FASTac
  • News
    • News
    • Awards
    • Media
    • PR Contact
  • Partnership
    • Collaboration
    • Contact us
  • Investors
  • Join Us
    • Openings
  • Contact
Kevin Pan, Ph.D.

Founder, Chairman, CEO

> Asieris Management Team
×

Over 20 years of successful track record in biotech start-up, drug R&D, and business development.

Founding member of Hutchison Medipharma (Shanghai). Served as Senior Director of Medicinal Chemistry and Executive Director of IP, and contributed to the clinical development of two drugs in the US. Later served as Executive Director of the Business Development department and successfully established strategic partnership with Procter & Gamble, MSD Germany, and Eli Lilly and Company. In 2006, served as core member of the IPO team in successfully raising 40 million pounds in the UK stock market.

Senior Scientist at Johnson & Johnson and Pfizer, with one responsible drug candidate completed Phase II clinical trial in the US.

Ph.D. in bio-organic chemistry from Rutgers, the State University of New Jersey. BS in chemistry from Fudan University.

PrevJohn Zhuang, Ph.D.